Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EGFR Antibody Combined With Programmed Death-1 Inhibitor and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Multi-center, Phase I/II Clinical Trial

NCT06802835 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06802835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06802835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EGFR Antibody Combined With Programmed Death-1 Inhibitor and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Multi-center, Phase I/II Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 9, 2025
Completion date
June 30, 2029
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nasopharyngeal carcinoma, nasopharyngeal cancinoma (npc), recurrent nasopharynx carcinoma